{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T15:54:22Z","timestamp":1766073262073,"version":"3.48.0"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Tafenoquine, an 8\u2010aminoquinoline antimalarial, represents a promising advancement in combating malaria, but its bitter taste and lack of paediatric formulations hinder effective treatment for children. In response, we have formulated a chocolate\u2010based chewable tafenoquine tablet for paediatric use. A rapid, stability\u2010indicating high\u2010performance liquid chromatography method with ultraviolet detection was developed and validated for tafenoquine succinate quantification. Tablet samples were extracted with 85% methanol and analysed on a Waters XBridge C18 (150\u2009\u00d7\u20094.6\u2009mm, 5\u2009\u03bcm) column using an isocratic mobile phase of 50\u2009mM potassium dihydrogen orthophosphate buffer (pH\u20094.5) and acetonitrile (40:60, v\/v). Detection was at 254\u2009nm, with a retention time of 4.3\u2009min. The method was linear over 0\u2013313.6\u2009\u03bcg\/mL (\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    \u2009\u2265\u20090.999) with limits of detection and quantification of 2.22 and 6.73\u2009\u03bcg\/mL, respectively. Precision (RSD 0.15%\u20131.35%) and accuracy (101.48%\u2013101.90%) met International Council for Harmonisation Q2 (R2) criteria. Forced degradation showed tafenoquine's susceptibility to acidic (29.33%), basic (18.83%), photolytic (complete degradation by day 14), and oxidative (8.33%) stress, with complete chromatographic separation from degradation products. This robust, rapid and low\u2010cost assay is suitable for routine content and stability testing, is adaptable to other tafenoquine formulations and can be further applied to clinical settings.\n                  <\/jats:p>","DOI":"10.1002\/bmc.70303","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:04:03Z","timestamp":1765281843000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and Validation of a Stability\u2010Indicating HPLC\u2010UV Assay for Quantification of Tafenoquine Succinate in a Novel Paediatric Antimalarial Formulation"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2539-2042","authenticated-orcid":false,"given":"Madison\u00a0L.","family":"Bartlett","sequence":"first","affiliation":[{"name":"Curtin Medical School Curtin University  Bentley Western Australia Australia"},{"name":"Curtin Medical Research Institute Curtin University  Bentley Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhu","family":"Page\u2010Sharp","sequence":"additional","affiliation":[{"name":"Curtin Medical School Curtin University  Bentley Western Australia Australia"},{"name":"Curtin Medical Research Institute Curtin University  Bentley Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Okhee","family":"Yoo","sequence":"additional","affiliation":[{"name":"Pharmacy, School of Allied Health University of Western Australia  Perth Western Australia Australia"},{"name":"Institute for Paediatric Perioperative Excellence The University of Western Australia  Perth Western Australia Australia"},{"name":"Wesfarmers Centre for Vaccines and Infectious Diseases The Kids Research Institute  Nedlands Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minh\u00a0N.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Pharmacy, School of Allied Health University of Western Australia  Perth Western Australia Australia"},{"name":"Institute for Paediatric Perioperative Excellence The University of Western Australia  Perth Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee\u00a0Yong","family":"Lim","sequence":"additional","affiliation":[{"name":"Curtin Medical School Curtin University  Bentley Western Australia Australia"},{"name":"Pharmacy, School of Allied Health University of Western Australia  Perth Western Australia Australia"},{"name":"Institute for Paediatric Perioperative Excellence The University of Western Australia  Perth Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brioni\u00a0R.","family":"Moore","sequence":"additional","affiliation":[{"name":"Curtin Medical School Curtin University  Bentley Western Australia Australia"},{"name":"Curtin Medical Research Institute Curtin University  Bentley Western Australia Australia"},{"name":"Wesfarmers Centre for Vaccines and Infectious Diseases The Kids Research Institute  Nedlands Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/424663"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2017.07.009"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2017.10.060"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010200225010\u201000001"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002379"},{"key":"e_1_2_9_7_1","unstructured":"European Medicines Agency2024. \u201cICH Q2(R2) Guideline on Validation of Analytical Procedures.\u201d Retrieved fromhttps:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/ich\u2010q2r2\u2010guideline\u2010validation\u2010analytical\u2010procedures\u2010step\u20105\u2010revision\u20101_en.pdf."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010018\u20100979\u20102"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2010.09\u20100521"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013\u20103225"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.53555\/ecb\/2022.11.01.18"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802537"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(13)62568\u20104"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/anae.14318"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0021\u20109673(02)01536\u20104"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.25004\/IJPSDR.2022.140405"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2016.04.009"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651\u20102227.1999.tb00191.x"},{"key":"e_1_2_9_19_1","unstructured":"U.S. Food and Drug Administration.2018. \u201cHighlights of Prescribing Information for ARAKODA (Tafenoquine) Tablets.\u201d Retrieved fromhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210607lbl.pdf."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20104642(21)00328\u2010x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/anae.15650"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.70303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T15:49:21Z","timestamp":1766072961000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.70303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/bmc.70303"],"URL":"https:\/\/doi.org\/10.1002\/bmc.70303","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"type":"print","value":"0269-3879"},{"type":"electronic","value":"1099-0801"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"2025-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70303"}}